Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment
Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients.
Bemdaneprocel therapy is at an early stage, and the year-long trial involved just 12 patients, but the positive outcome is viewed as significant after decades of setbacks in the hunt for an effective treatment. Developed by BlueRock therapeutics, a subsidiary of the pharmaceutical company Bayer, it was shown to be safe and the data gave a tantalising suggestion that patients may have benefited.
About Author
More Stories
Male mosquitoes to be genetically engineered to poison females with semen in Australian research
Bizarre Australian mole even more unusual than first thought, new research reveals
Memo to Trump: US telecoms is vulnerable to hackers. Please hang up and try again | John Naughton